These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28680748)

  • 1. MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.
    Brandetti E; Veneziani I; Melaiu O; Pezzolo A; Castellano A; Boldrini R; Ferretti E; Fruci D; Moretta L; Pistoia V; Locatelli F; Cifaldi L
    Oncoimmunology; 2017; 6(6):e1316439. PubMed ID: 28680748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BET-bromodomain inhibitor JQ1 renders neuroblastoma cells more resistant to NK cell-mediated recognition and killing by downregulating ligands for NKG2D and DNAM-1 receptors.
    Veneziani I; Fruci D; Compagnone M; Pistoia V; Rossi P; Cifaldi L
    Oncotarget; 2019 Mar; 10(22):2151-2160. PubMed ID: 31040907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of Neuroblastoma NK-Cell-Mediated Lysis through NF-kB p65 Subunit-Induced Expression of FAS and PVR, the Loss of Which Is Associated with Poor Patient Outcome.
    Brandetti E; Focaccetti C; Pezzolo A; Ognibene M; Folgiero V; Cotugno N; Benvenuto M; Palma P; Manzari V; Rossi P; Fruci D; Bei R; Cifaldi L
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
    Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
    Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
    Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
    Veneziani I; Brandetti E; Ognibene M; Pezzolo A; Pistoia V; Cifaldi L
    J Immunol Res; 2018; 2018():4972410. PubMed ID: 29805983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches.
    Bottino C; Dondero A; Bellora F; Moretta L; Locatelli F; Pistoia V; Moretta A; Castriconi R
    Front Immunol; 2014; 5():56. PubMed ID: 24575100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
    Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
    Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells
    Focaccetti C; Benvenuto M; Pighi C; Vitelli A; Napolitano F; Cotugno N; Fruci D; Palma P; Rossi P; Bei R; Cifaldi L
    Front Immunol; 2022; 13():886319. PubMed ID: 35967339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
    Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
    Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
    Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
    Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.
    Manohar CF; Salwen HR; Brodeur GM; Cohn SL
    Genes Chromosomes Cancer; 1995 Nov; 14(3):196-203. PubMed ID: 8589036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
    Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
    Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
    Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
    Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
    Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
    Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
    Hallett RM; Seong AB; Kaplan DR; Irwin MS
    Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Raieli S; Di Renzo D; Lampis S; Amadesi C; Montemurro L; Pession A; Hrelia P; Fischer M; Tonelli R
    Front Oncol; 2021; 11():625207. PubMed ID: 33718189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.
    Cappel C; Huenecke S; Suemmerer A; Erben S; Rettinger E; Pfirrmann V; Heinze A; Zimmermann O; Klingebiel T; Ullrich E; Bader P; Bremm M
    Pediatr Blood Cancer; 2016 Dec; 63(12):2230-2239. PubMed ID: 27433920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Efficacy of Histone Methyltransferase G9a Inhibitors Against
    Bellamy J; Szemes M; Melegh Z; Dallosso A; Kollareddy M; Catchpoole D; Malik K
    Front Oncol; 2020; 10():818. PubMed ID: 32537432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.